Benznidazole
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 329662

CAS#: 22994-85-0

Description: Benznidazole is an antiparasitic medication used in the treatment of Chagas disease. While it is highly effective in early disease this decreases in those who have long term infection. It is the first line treatment given its moderate side effects compared to nifurtimox. It is taken by mouth. Benznidazole is a nitroimidazole antiparasitic with good activity against acute infection with Trypanosoma cruzi, commonly referred to as Chagas disease. Like other nitroimidazoles, benznidazole's main mechanism of action is to generate radical species which can damage the parasite's DNA or cellular machinery. The mechanism by which nitroimidazoles do this seems to depend on whether or not oxygen is present. This is particularly relevant in the case of Trypanosoma species, which are considered facultative anaerobes.


Chemical Structure

img
Benznidazole
CAS# 22994-85-0

Theoretical Analysis

MedKoo Cat#: 329662
Name: Benznidazole
CAS#: 22994-85-0
Chemical Formula: C12H12N4O3
Exact Mass: 260.09
Molecular Weight: 260.253
Elemental Analysis: C, 55.38; H, 4.65; N, 21.53; O, 18.44

Price and Availability

Size Price Availability Quantity
200mg USD 250 2 weeks
500mg USD 450 2 weeks
1g USD 650 2 weeks
2g USD 1050 2 weeks
Bulk inquiry

Synonym: Benznidazole; NSC 299972; NSC-299972; NSC299972; Radanil; RO 07-1051; RO-07-1051; RO07-1051; RO 071051; RO-071051; RO071051; Rochagan.

IUPAC/Chemical Name: 2-Nitro-N-(phenylmethyl)-1H-imidazole-1-acetamide

InChi Key: CULUWZNBISUWAS-UHFFFAOYSA-N

InChi Code: InChI=1S/C12H12N4O3/c17-11(14-8-10-4-2-1-3-5-10)9-15-7-6-13-12(15)16(18)19/h1-7H,8-9H2,(H,14,17)

SMILES Code: O=C(NCC1=CC=CC=C1)CN2C=CN=C2[N+]([O-])=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 260.25 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Available from http://www.ncbi.nlm.nih.gov/books/NBK548076/ PubMed PMID: 31643406.

2: Arrúa EC, Seremeta KP, Bedogni GR, Okulik NB, Salomon CJ. Nanocarriers for effective delivery of benznidazole and nifurtimox in the treatment of chagas disease: A review. Acta Trop. 2019 Oct;198:105080. doi: 10.1016/j.actatropica.2019.105080. Epub 2019 Jul 9. Review. PubMed PMID: 31299283.

3: Kratz JM, Garcia Bournissen F, Forsyth CJ, Sosa-Estani S. Clinical and pharmacological profile of benznidazole for treatment of Chagas disease. Expert Rev Clin Pharmacol. 2018 Oct;11(10):943-957. doi: 10.1080/17512433.2018.1509704. Epub 2018 Sep 19. Review. PubMed PMID: 30111183.

4: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from http://www.ncbi.nlm.nih.gov/books/NBK500652/ PubMed PMID: 29999711.

5: Scarim CB, Ribeiro AR, Rosa JAD, Chin CM. Response to different benznidazole doses in animal models of chronic phase Chagas disease: a critical review. Rev Soc Bras Med Trop. 2018 Mar-Apr;51(2):133-140. doi: 10.1590/0037-8682-0337-2017. Review. PubMed PMID: 29768544.

6: Thakare R, Dasgupta A, Chopra S. An update on benznidazole for the treatment of patients with Chagas disease. Drugs Today (Barc). 2018 Jan;54(1):15-23. doi: 10.1358/dot.2018.54.1.2753402. Review. PubMed PMID: 29569658.

7: Ferraz LRM, Alves AÉG, Nascimento DDSDS, Amariz IAE, Ferreira AS, Costa SPM, Rolim LA, Lima ÁAN, Rolim Neto PJ. Technological innovation strategies for the specific treatment of Chagas disease based on Benznidazole. Acta Trop. 2018 Sep;185:127-132. doi: 10.1016/j.actatropica.2018.02.008. Epub 2018 Feb 13. Review. PubMed PMID: 29452113.

8: Olivera MJ, Fory JA, Olivera AJ. Therapeutic drug monitoring of benznidazole and nifurtimox: a systematic review and quality assessment of published clinical practice guidelines. Rev Soc Bras Med Trop. 2017 Nov-Dec;50(6):748-755. doi: 10.1590/0037-8682-0399-2016. Review. PubMed PMID: 29340450.

9: Pérez-Molina JA, Pérez-Ayala A, Moreno S, Fernández-González MC, Zamora J, López-Velez R. Use of benznidazole to treat chronic Chagas' disease: a systematic review with a meta-analysis. J Antimicrob Chemother. 2009 Dec;64(6):1139-47. doi: 10.1093/jac/dkp357. Epub 2009 Oct 9. Review. PubMed PMID: 19819909.

10: Viotti R, Vigliano C, Lococo B, Alvarez MG, Petti M, Bertocchi G, Armenti A. Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities. Expert Rev Anti Infect Ther. 2009 Mar;7(2):157-63. doi: 10.1586/14787210.7.2.157. Review. PubMed PMID: 19254164.

11: Mady C, Ianni BM, de Souza JL Jr. Benznidazole and Chagas disease: can an old drug be the answer to an old problem? Expert Opin Investig Drugs. 2008 Oct;17(10):1427-33. doi: 10.1517/13543784.17.10.1427 . Review. PubMed PMID: 18808305.

12: Nishioka Sde A. [Benznidazole in the primary chemoprophylaxis of the reactivation of Chagas' disease in chronic chagasic patients using corticosteroids at immunosuppressive doses: is there sufficient evidence for recommending its use?]. Rev Soc Bras Med Trop. 2000 Jan-Feb;33(1):83-5. Review. Portuguese. PubMed PMID: 10881124.

13: Castro JA, Diaz de Toranzo EG. Toxic effects of nifurtimox and benznidazole, two drugs used against American trypanosomiasis (Chagas' disease). Biomed Environ Sci. 1988 Jun;1(1):19-33. Review. PubMed PMID: 3151755.